Generic Rx Reforms: No Automatic “Controversy” For Declaratory Judgments
Executive Summary
The Medicare conference bill's Waxman/Hatch reform provisions would require federal courts to determine whether declaratory judgment actions brought by ANDA filers against innovators are a "case or controversy" under the Constitution
You may also be interested in...
Declaratory Judgment Ruling Will Add Uncertainty To Generic Launches
Generic companies are likely to face an increased threat of patent infringement lawsuits on the eve of launch following an appeals court ruling on the standards for seeking a declaratory judgment of noninfringement
Declaratory Judgment Ruling Will Add Uncertainty To Generic Launches
Generic companies are likely to face an increased threat of patent infringement lawsuits on the eve of launch following an appeals court ruling on the standards for seeking a declaratory judgment of noninfringement
Generic Industry Faces Downturn, Sandoz Says; MMA Changes Hurt
The generic industry is facing a "downturn" in the market for products with low barriers to entry, Sandoz CEO Andreas Rummelt said Jan. 20